diff --git a/pages/STOP2030___Web___Update 2024___02.md b/pages/STOP2030___Web___Update 2024___02.md
index 5ade8453..51e06d3e 100644
--- a/pages/STOP2030___Web___Update 2024___02.md	
+++ b/pages/STOP2030___Web___Update 2024___02.md	
@@ -88,7 +88,7 @@
 			- Especificar que esta fixed-dose coformulation de ivm/alb has the lowest [[level]] of investment risk of all candidates for Combinations for [[STH]] treatment (fuente: Soil Transmitted Helminths Drug Combinations Expert Meeting, 2016, Gates Foundation)
 			- Una referencia explícita al Estudio ALIVE: https://gatesopenresearch.org/articles/6-62/v1
 			- Los achievements de los STOP previos
-				- Qualification at EMA for [[article]] 58 (ahora se llama Meds4All, creo)
+				- Qualification at EMA for [[article]] 58 (ahora se llama Meds4All, creo) https://www.ema.europa.eu/en/glossary/article-58-application https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/medicines-use-outside-european-union
 				- Proved safety of ivermectin of up to 600ug/kg both alone and in coformulation with [[albendazole]]
 				- Demonstrated efficacy of the [[FDC]] against T. trichiura
 			-